Brookline Capital Management Forecasts Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Equities researchers at Brookline Capital Management issued their Q1 2025 earnings estimates for Genelux in a note issued to investors on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.20) per share for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.16) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Genelux in a research report on Tuesday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $18.25.

Genelux Trading Down 5.3 %

GNLX stock opened at $3.03 on Thursday. Genelux has a 12 month low of $1.60 and a 12 month high of $6.50. The stock has a market cap of $104.65 million, a PE ratio of -3.19 and a beta of -1.41. The company has a 50-day moving average price of $4.05 and a 200 day moving average price of $3.09.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in Genelux by 39.7% during the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after buying an additional 89,854 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Genelux by 51.4% during the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after acquiring an additional 52,958 shares in the last quarter. LPL Financial LLC boosted its holdings in shares of Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after purchasing an additional 39,516 shares during the period. LifeSteps Financial Inc. grew its stake in Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after purchasing an additional 8,715 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Genelux during the 3rd quarter worth $59,000. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.